woman in laboratory

We translate MYC synthetic lethality into biomarker-driven cancer therapies that deliver meaningful clinical benefit

INTEGRATED INSTITUTE
COMPANY MODEL

SYMPLEX™ SYSTEMS
DRIVEN DISCOVERY ENGINE

DIVERSE & EXPANDING
MYC-SL PIPELINE

BIOMARKER-EMBEDDED
CLINICAL STRATEGY

At Anticancer Bioscience, we believe cancer’s greatest strengths can also create its deepest vulnerabilities. Rather than focusing only on the mutations and pathways that drive cancer, we seek the essential dependencies that cancer cells cannot live without – their true Achilles’ heels. By pioneering new concepts and technologies to uncover and exploit these vulnerabilities, we are translating MYC synthetic lethality into biomarker-driven therapies with the potential to transform cancer treatment.

LATEST NEWS
01 September 2026
Anticancer Bioscience Receives IND Clearance in China for First-in-Human Trial of JMBI-001
30 July 2026
Anticancer Bioscience Announces JMBI-001 IND Acceptance Under China’s Expedited Review Pathway
If you require more information or would like to get in touch please email us